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doi:10.1016/j.ejvs.2010.12.012Abstract Objectives: The aim of this work was to quantify the volume of blood required to
deactivate 1 ml of 3% sodium tetradecyl sulphate (STS).
Design: A series of experiments were performed where the concentration of STS remaining in
a stock solution was measured after adding increasing volumes of blood protein solutions.
Materials and methods: Increasing volumes of bovine serum albumin, bovine erythrocytes and
a mixture of both was added to a stock solution of STS. The BP manual titration method was
used to measure the assay of the remaining STS.
Results: The method was reproducible and increasing volumes of blood protein lowered the
STS concentration in a linear fashion. Approximately 2 ml of a 4% blood protein solution deac-
tivates 1 ml of 3% STS, which means approximately 0.5 ml of whole blood will deactivate 1 ml
of 3% STS.
Conclusions: Sodium tetradecyl sulphate injection is deactivated by a relatively small volume
of blood. The practical implication is that changes in technique to reduce the blood volume in
larger veins and to introduce fresh aliquots of sclerosant along the length of the vein could
improve the efficacy of sclerotherapy.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Injection into a blood vessel was first described by Pravaz in
1853when he injected ferric chloride into an aneurysm.Over
the next hundred years many different sclerosing agents
were tried for the treatment of varicose veins with varying
degrees of success.1 The use of sodium tetradecyl sulphate
(STS) as a sclerosant was described in 1946 and its use soon432 373 556.
harm.co.uk.
ty for Vascular Surgery. Publishebecame popular.2 Sclerosants containing STS as the active
ingredient are now widely used around the world.
Irish surgeon George Fegan published the results of his
‘Continuous compression technique of injecting varicose
veins’ using STS in 1963.3 He had a fastidious technique and
was especially particular that the vein to be treated should
be free of blood, often referred to as ‘the empty vein
technique’. From in-vitro work he concluded that STS binds
with plasma proteins and is deactivated, consequently the
section of vein to be treated should be free of blood.4
Following initial enthusiasm, the use of sclerotherapy to
treat large varicose veins and truncal veins declined andd by Elsevier Ltd. All rights reserved.
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more robust.5 It was thought that in larger veins the liquid
sclerosant mixed with the blood was diluted, deactivated
and unable to damage the endothelium.
Some elegant in vitro work by Parsi and colleagues
confirmed Fegan’s belief that the action of STS is indeed
inhibited by blood proteins.6 They studied the effect of
increasing concentrations of sclerosant on cultured endothe-
lial cells and red blood cells with and without the addition of
albumin or blood plasma. A higher concentration of STS was
required todamage thecells in thepresenceofbloodproteins.
It is clear that blood proteins deactivate STS. However
the effect of whole blood on working concentrations of STS
injection has not been established. Therefore the aim of
this study was to quantify the volume of blood required to
neutralise 1 ml of 3% STS injection.Figure 1 Start point of titration the indicator is pink.
Figure 2 End point of titration the indicator turns blue.Materials and Methods
There are two in house methods at STD Pharmaceutical Prod-
ucts for measuring the concentration of sodium tetradecyl
sulphate in solution. One method involves the use of an auto-
titration machine; the other method is to perform a standard
manual titration as listed in the British Pharmacopeia for
sodium tetradecyl sulphate concentrate and injection.7
In pilot experiments to develop a reliable method of
measuring the residual concentration of STS in solution
after the addition of protein, increasing volumes of a 1.6%
bovine serum albumin (BSA) solution were added to a stock
solution of 20 ml of 0.12% STS and then the concentration of
the STS in the mixture was measured.
The auto-titrator method was used first and gave read-
ings when a small amount of the BSA solution was added. As
more BSA solution was added it became impossible to
obtain an end reading, probably because the protein was
interfering with the probe.
The next pilot experiment used the manual titration
method as described in the BP monograph for sodium tetra-
decyl sulphate injection. A stock solution of 20ml of 0.12% STS
was prepared in a conical flask and to this solution an indi-
cator solution was added (chloroform and dimidium bromi-
deesulphan blue solution). The indicator solution changed
from pink (Fig. 1) to grayish blue (Fig. 2) as the STS was
deactivated by the addition of hyamine (0.004 m) from
a burette. The concentration of STS in the solution was
calculated by measuring the amount of hyamine required to
deactivate the STS. Each ml of hyamine being equivalent to
1.266 mg of STS. Five titrations were made where increasing
volumes of a 1.6% BSA solution was added to the stock STS
solution.
The end point colour change from pink to grey/blue was
more difficult to read as the albumin levels increased but
the results gave good linearity in the pilot experiments.
Three experiments using the BP manual titration method
were performed to quantify the concentration of free STS
remaining in solution after the addition of:
1. increasing volumes of a BSA solution
2. increasing volumes of a solution of reconstituted dried
bovine erythrocytes
3. increasing volumes of a simulated blood solution.Exp. 1. The BSA solution was made from albumin bovine
serum lyophilised powder (Sigma Aldrich product number
A9647 Batch No. 076K0717) dissolved in de-ionised water at
a concentration of 1.6%w/v. A BSA concentration of 1.6%was
used because it gave a good working range in pilot experi-
ments. The stock solution of 0.12% STS was made from 10 ml
of 3% Fibro-Vein, batch 7K032, in 250 ml of de-ionised water.
Exp. 2. The erythrocyte solution was made by dissolving
dried bovine erythrocytes (Sigma Aldrich product number
H3760 Batch No. 077K0676) in de-ionised water at a concen-
tration of 1.6% w/v.
Exp. 3. The third experiment involved making a solution
of BSA and erythrocytes to mimic a blood solution. It was
assumed that blood comprises of approximately 20% protein
and a simulated laboratory blood was made up of 4%
albumin plus 16% erythrocytes. The solution was then
diluted to give an overall protein concentration of 1.6% for
the titration. The batch of Fibro-Vein used to create the
stock STS solution was 8B046.
For each of the experiments individual titrations were
made following the addition of 0, 1, 2, 3 and 4 ml of one of
the protein solutions to a fresh solution of 0.12% STS. The
titration began approximately 15 s after adding and mixing
the protein solution to the STS solution.
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Figure 4 STS assay after adding increasing volumes of an
erythrocyte solution to a stock STS solution.
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were made for each point. For the blood solution four titra-
tions were made for each point.
Statistical methods
The average titre result for each volume of protein solution
added and the standard deviation were calculated using
Microsoft Excel 2003. The same software was used to plot
the results and to calculate the best fit trend line as well as
the correlation coefficient between the volume of protein
added versus average titre result. The error bars on the
graphs are þ/ one standard deviation.
Results
Experiment 1
The addition of albumin caused some precipitation in the
solution but end points were quite clear. A plot of the
average result of three individual titrations for each point is
presented in Fig. 3.
The linear trend line has a correlation coefficient off
0.998. Extension of the trend line gives an endpoint of
4.23 ml of 1.6% albumin to neutralise all of the STS.
Thus 42.3 ml of 0.16% albumin solution would neutralise
20 ml of 0.12% STS solution, which is the equivalent of
2.12 ml of 4% BSA to neutralise 1 ml of 3% STS. The result
has been converted to 4% BSA out of practical interest
because it is the concentration of albumin in blood.
Experiment 2
Increasing volumes of the erythrocyte solution caused quite
a lot of precipitation and the end points were more difficult
to determine which can be seen in the error bars on the
graph. A plot of the average result of three individual titra-
tions for each point is presented in Fig. 4.
Despite the difficulty determining the end points the
combined results gave a linear trend line correlation coef-
ficient off 1.000. Extension of the trend line gives anSTS assay after adding
1.6% bovine serum albumin solution
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Figure 3 STS assay after adding increasing volumes of BSA to
a stock STS solution.endpoint of 4.79 ml of 1.6% erythrocyte solution to
neutralise all of the STS.
Thus 47.9 ml of 0.16% erythrocyte solution neutralises
20 ml of 0.12% STS solution, which is the equivalent of
2.40 ml of 4% erythrocyte solution to neutralise 1 ml of 3%
STS.
Experiment 3
The addition of a laboratory blood solution caused quite
a lot of precipitation in the solution and the end points
were more difficult to determine which can be seen in the
error bars on the graph. A plot of the average result of four
individual titrations for each point is presented in Fig. 5
(NB titrations 3 and 4 were performed the day following
titrations 1 and 2).
The linear trend line has a correlation coefficient of
0.998. Extension of the trend line gives an endpoint of
4.29 ml of 1.6% lab blood to neutralise all of the STS.
Thus 2.15 ml of 0.16% lab blood solution neutralises
20 ml of 0.12% STS solution, which is the equivalent of
2.15 ml of 4% lab blood to neutralise 1 ml of 3% STS.
A summary of the results is shown in Table 1 in terms of
the volume of a 4% protein solution required to neutralise
1 ml of a 3% STS solution.STS assay after adding 1.6% blood solution
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
Volume 1.6% blood solution added - ml
% STS
Figure 5 STS assay after adding increasing volumes of
a laboratory blood solution to a stock STS solution.
Table 1 Volume of protein solution required to neutralise
1 ml of 3% STS injection.
Protein solution added Volume
4% bovine serum albumin 2.12 ml
4% bovine erythrocytes 2.40 ml
4% laboratory blood 2.15 ml
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4% protein, to whole blood at approximately 20% protein the
results suggest that only 0.43 ml of whole blood would be
required to neutralise 1 ml of 3% STS.
Discussion
The results show that STS is deactivated by blood proteins
in a linear fashion. The protein source (bovine serum
albumin or red blood cells) seemed to make little differ-
ence with just over 2 ml of a 4% protein solution deacti-
vating 1 ml of a 3% STS solution.
It is assumed the titration measured the free STS
remaining in solution after the addition of a blood protein
which would bind and deactivate some of the STS. The
repeatability and linearity of the results would suggest that
this is a reasonable assumption but nonetheless it could be
a source for error. The main source of error was visually
determining the end point of the titration with increasing
volumes of blood proteins which is why the average of three
(or four) individual readings was used. The results should
perhaps be used as a guide rather than an exact figure.
What these results suggest is that in practice it would
take less than 0.5 ml of whole blood to deactivate 1 ml of
3% STS, which would explain why an empty vein technique
is important when injecting liquid sclerosant into varicose
veins.
Parsi et al. investigated the effects of BSA and human
blood plasma on the lytic effects of STS on red blood cells,
platelets and cultured endothelial cells.6 Their results
showed that a 33 fold increase in the concentration of STS
was required to lyse red blood cells in the presence of BSA
versus just saline. The addition of whole blood required
a 50 fold increase in the STS concentration. This work
showed that BSA and other blood proteins deactivate STS
and supports the findings of Parsi et al.
They concluded that 5 ml of blood would have enough
plasmaproteins toneutralise1ml3%STS.Thisworkconcludes
that just over 2 ml of 4% BSA would do the same thing.
The main difference between the work of Parsi et al. and
this work is that they were measuring the lytic effects of
sclerosants on blood and endothelial cells in the presence of
blood protein whereas this work quantifies the residual STS
remaining after the addition of protein to a standard STS
solution. Given the differences in the experimental methods
it is difficult to draw direct comparisons between the results.
However taking both sets of results it is clear that a relatively
lowvolume of blood (0.5e1ml) is enough to neutralise 1ml of
3% STS.
In his book, ‘Varicose Veins: Compression Sclerotherapy’,
Fegan refers to the results of someexperiments on the action
of STS and quotes ‘Addition of STS to serum proteins causedturbidity, and subsequent electrophoresis showed abnormal
migration of the protein fractions. The reaction, which is
very rapid, appears to be a combination of STS and plasma
protein. As a result there is a complete inhibition of the
detergent properties of the sclerosant’.4 The work by Parsi
et al. and the results of these experiments support Fegan’s
findings.
What practical implications do these results have? Studies
have shown that ultrasound guided foam sclerotherapy is
more effective than liquid sclerotherapy.8 It is generally
believed that the foam displaces the blood better than liquid
which mixes with the blood and becomes deactivated.
However foam sclerotherapy becomes less effective as veins
get larger.9e11 Larger veins can be treated but it may take
more sessions. It seems likely that as the veins get larger
foam is less effective at displacing blood and the sclerosant
becomes deactivated as it does in liquid form.
The results suggest that practical techniques for reducing
the blood volume in a vein as well as introducing fresh
sclerosant along its length may have an advantage particu-
larly when treating larger veins. For example, the use of
tumescent compression around a truncal vein to reduce the
blood volume and introducing sclerosant along its length via
a catheter.12,13
Conclusion
Sodium tetradecyl sulphate injection is deactivated by
a relatively small volume of blood, 1 ml of 3% STS is deac-
tivated by less than 0.5 ml of a simulated laboratory blood.
The practical implication is that changes in technique to
reduce the blood volume in larger veins and to introduce
fresh sclerosant along the length of the vein could improve
the results of sclerotherapy.
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